Source: http://www.cancer.gov/images/cdr/live/CDR763079-750.jpg
The AP (11/17, Johnson) reports that the Food and Drug Administration approved Johnson & Johnson’s Darzalex (daratumumab), a drug “for treating the incurable blood cancer multiple myeloma in patients who’ve failed prior therapies and have few options left.” The drug is not only the first biologic, but also the first monoclonal antibody approved to treat multiple myeloma.
Also covering the story are Reuters (11/17, Pierson), HealthDay (11/17, Roberts), MedPage Today (11/17, Bankhead), and Medscape (11/17, Chustecka).
No comments:
Post a Comment